ATE381322T1 - Verfahren zur stabilisierung von atorvastatin - Google Patents

Verfahren zur stabilisierung von atorvastatin

Info

Publication number
ATE381322T1
ATE381322T1 AT04738465T AT04738465T ATE381322T1 AT E381322 T1 ATE381322 T1 AT E381322T1 AT 04738465 T AT04738465 T AT 04738465T AT 04738465 T AT04738465 T AT 04738465T AT E381322 T1 ATE381322 T1 AT E381322T1
Authority
AT
Austria
Prior art keywords
kpa
preferably less
partial pressure
gaseous mixture
oxygen
Prior art date
Application number
AT04738465T
Other languages
English (en)
Inventor
Pavel Sebek
Alena Prokopova
Eduard Svoboda
Stanislav Radl
Jan Stach
Martin Svoboda
Andrej Kovacik
Adrian Danko
Roman Petro
Miroslav Strizinec
Original Assignee
Zentiva As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34117186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE381322(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ20032135A external-priority patent/CZ295027B6/cs
Priority claimed from CZ20040857A external-priority patent/CZ296181B6/cs
Application filed by Zentiva As filed Critical Zentiva As
Application granted granted Critical
Publication of ATE381322T1 publication Critical patent/ATE381322T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT04738465T 2003-08-05 2004-08-05 Verfahren zur stabilisierung von atorvastatin ATE381322T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20032135A CZ295027B6 (cs) 2003-08-05 2003-08-05 Způsob stabilizace farmaceutické kompozice
CZ20040857A CZ296181B6 (cs) 2004-08-03 2004-08-03 Zpusob stabilizace farmaceutické úcinné tuhé látky atorvastatinu

Publications (1)

Publication Number Publication Date
ATE381322T1 true ATE381322T1 (de) 2008-01-15

Family

ID=34117186

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04738465T ATE381322T1 (de) 2003-08-05 2004-08-05 Verfahren zur stabilisierung von atorvastatin

Country Status (13)

Country Link
US (1) US20080171784A1 (de)
EP (1) EP1653930B1 (de)
AT (1) ATE381322T1 (de)
CA (1) CA2535225A1 (de)
DE (1) DE602004010817T2 (de)
EA (1) EA007345B1 (de)
ES (1) ES2298763T3 (de)
HR (1) HRP20060089B1 (de)
PL (2) PL1653930T3 (de)
PT (1) PT1653930E (de)
RS (1) RS20060081A (de)
SK (1) SK50462005A3 (de)
WO (1) WO2005011638A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100923939B1 (ko) * 2004-09-28 2009-10-29 테바 파마슈티컬 인더스트리즈 리미티드 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
EP1741427A1 (de) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
CZ300047B6 (cs) * 2007-03-02 2009-01-21 Zentiva, A. S. Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
EP2127628A1 (de) 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Einheitsdosenverpackung
TR200806300A2 (tr) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Çözünürlük artırıcı farmasötlk formulasyon
US20120244220A1 (en) 2009-12-25 2012-09-27 Sawai Pharmaceutical Co., Ltd. Atrovastatin-containing coated preparation
WO2013083674A1 (de) * 2011-12-08 2013-06-13 Hexal Ag Neue pharmazeutische statin-zusammensetzung
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
EP3143988A1 (de) 2013-03-14 2017-03-22 Fresenius Kabi Deutschland GmbH Injizierbare morphinformulierungen
EP3424547B1 (de) 2013-03-14 2026-02-11 Fresenius Kabi Austria GmbH Verpackungssystem für sauerstoffempfindliche medikamente
EP3184103A1 (de) 2015-12-21 2017-06-28 Hexal AG Pharmazeutische zusammensetzung mit atorvastatin oder einem salz davon
EP3272336A1 (de) 2016-07-19 2018-01-24 Stada Arzneimittel Ag Atorvastatin-zusammensetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
ATE178794T1 (de) * 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
WO2001093859A1 (en) * 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
EP1241110A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Ausgabeeinheit für sauerstoff-empfindlichen Medikamenten
EP1243524A3 (de) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmazeutisches Kit fÜr sauerstoffempfindliche Medikamente
WO2003068191A1 (en) * 2002-02-14 2003-08-21 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Also Published As

Publication number Publication date
DE602004010817D1 (de) 2008-01-31
HRP20060089B1 (en) 2008-05-31
DE602004010817T2 (de) 2008-12-11
HRP20060089A2 (en) 2006-05-31
PL379195A1 (pl) 2006-07-24
EA007345B1 (ru) 2006-08-25
EP1653930A2 (de) 2006-05-10
WO2005011638A2 (en) 2005-02-10
SK50462005A3 (sk) 2005-09-08
CA2535225A1 (en) 2005-02-10
US20080171784A1 (en) 2008-07-17
EP1653930B1 (de) 2007-12-19
ES2298763T3 (es) 2008-05-16
PL1653930T3 (pl) 2008-06-30
PT1653930E (pt) 2008-03-12
RS20060081A (sr) 2008-06-05
WO2005011638A3 (en) 2005-10-20
EA200500819A1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
ATE381322T1 (de) Verfahren zur stabilisierung von atorvastatin
AP1880A (en) Method for obtaining aqueous formulations of oxidation sensitive active principles.
GR3025966T3 (en) Method for manufacturing and storing stable bicarbonate solutions.
WO2008068411A3 (fr) Milieu d'extraction utilise dans un procede de capture de dioxyde de carbone contenu dans un effluent gazeux
GB0217587D0 (en) Porous beads and method of production thereof
MX295630B (es) Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
WO2005122774A3 (en) Packaging of meat prodcuts with modified atmospheres and/or enhancers
AR022866A1 (es) Conjunto que comprende una bebida envasada lista para beber y dicha bebida envasada lista para beber.
WO2007057595A3 (fr) Procédé de fonctionnalisation d'une portion de surface d'une fibre polymérique
MX172537B (es) Procedimiento y aparato mejorados para separar selectivamente por lo menos un gas con respecto a por lo menos otro gas en una mezcla gaseosa
DE50311227D1 (de) Aufenthaltsraum und verfahren zum einstellen der raumatmosphäre
AU2003301519A1 (en) Method and apparatus for filling portable high pressure cylinders with respiratory oxygen
AR041588A1 (es) Composicion farmaceutica estabilizada que comprende una sustancia activa amorfa
WO2004112649A3 (en) Method and apparatus for supplying gas to an area
PL1688146T3 (pl) Przygotowywanie aldesleukiny do zastosowania farmaceutycznego
EP1900641A3 (de) System zur Verpackung minimal behandelter frischer Gemüseprodukte
MY141989A (en) Drug delivery assembly
WO2006089108A3 (en) Method and apparatus for supplying gas to an area
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy
WO2007098350A3 (en) Method and apparatus for killing insects on fresh produce
WO2002026059A3 (en) Method for preserving food products using biological modified atmosphere packaging
WO2007044835A3 (en) Apparatus, system, and method for storage of mushrooms
DE60113710D1 (de) Verfahren und anlage zum verpacken einer flüssigkeit
CA2489738A1 (en) Modified atmosphere packaging for seafood
ECSP056120A (es) Procedimiento para la conservación de plátanos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties